New OWEAR Program Highlights Emerging De Facto Standards in Open-source Algorithms
The Open Wearables Initiative (OWEAR) announced a new program designed to identify and support open-source algorithms that are being adopted rapidly and may become de facto industry standards.
This OWEAR program uses the number and quality of references to “crowdsource” the identification of potential de facto standards. Once a potential standard is identified, OWEAR will create and maintain a searchable catalog that displays key information about the studies in which the algorithm has been employed, including the therapeutic area, population(s) studied, and number of participants.
OWEAR plans to create a new catalog for each open-source algorithm used in a wearable sensor or other connected health technology that generates more than 25 published papers and meets other quality metrics. The reference-count criterion indicates that the algorithm has garnered significant industry adoption. Shimmer Research, Inc. has agreed to donate the staff time to create and maintain these OWEAR catalogs.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
